Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Comparative Preclinical Evaluation of the Tumor-Targeting Properties of Radioiodine and Technetium-Labeled Designed Ankyrin Repeat Proteins for Imaging of Epidermal Growth Factor Receptor Expression in Malignant Tumors.

Title: Comparative Preclinical Evaluation of the Tumor-Targeting Properties of Radioiodine and Technetium-Labeled Designed Ankyrin Repeat Proteins for Imaging of Epidermal Growth Factor Receptor Expression in Malignant Tumors.
Authors: Larkina, Mariia; Yanovich, Gleb; Hasnowo, Lutfi Aditya; Varvashenya, Ruslan; Yuldasheva, Feruza; Tretyakova, Maria; Plotnikov, Evgenii; Zelchan, Roman; Schulga, Alexey; Konovalova, Elena; Ziganshin, Rustam; Belousov, Mikhail V; Tolmachev, Vladimir M.; Deyev, Sergey M
Publisher Information: Uppsala universitet, Institutionen för immunologi, genetik och patologi
Publication Year: 2025
Collection: Uppsala University: Publications (DiVA)
Subject Terms: DARPin E01; EGFR imaging; SPECT imaging; biodistribution; iodine-123; non-residualizing label; radiolabeling; residualizing label; technetium-99m; tumor targeting; Pharmacology and Toxicology; Farmakologi och toxikologi
Description: Radionuclide molecular imaging of epidermal growth factor receptor (EGFR) expression might permit the selection of patients for EGFR-targeting therapies. Designed ankyrin repeat protein (DARPin) E01 with a high affinity to the ectodomain III of the EGFR is a possible EGFR imaging probe. The goal of this study was to evaluate the potential of radiolabeled DARPin E01 for in vivo imaging of EGFR. DARPin E01 containing the (HE)3-tag was site-specifically labeled with a residualizing 99mTc (using 99mTc]Tc(CO)3). Two methods providing non-residualizing 123I labels, direct electrophilic radioiodination and indirect radioiodination using [123I]I-para-iodobenzoate (PIB), were tested. [99mTc]Tc-(HE)3-E01 and [123I]I-(HE)3-E01-PIB preserved specific binding to EGFR-expressing cells and affinity in the single-digit nanomolar range. Direct labeling with 123I resulted in a substantial loss of binding. In vitro cellular processing studies showed that both [99mTc]Tc-(HE)3-E01 and [123I]I-(HE)3-E01-PIB had rapid binding and relatively slow internalization. Evaluation of [99mTc]Tc-(HE)3-E01 biodistribution in normal CD1 mice showed that its hepatic uptake was non-saturable, suggesting that this tracer does not bind to murine EGFR. A side-by-side comparison of biodistribution and tumor targeting of [99mTc]Tc-(HE)3-E01 and [123I]I-(HE)3-E01-PIB was performed in Nu/j mice bearing EGFR-positive A-431 and EGFR-negative Ramos human cancer xenografts. Both radiolabeled DARPins demonstrated EGFR-specific tumor uptake. However, [123I]I-(HE)3-E01-PIB had appreciably lower uptake in normal organs compared to [99mTc]Tc-(HE)3-E01, which provided significantly (p < 0.05) higher tumor-to-organ ratios. Gamma-camera imaging confirmed that [123I]I-(HE)3-E01-PIB demonstrated a higher imaging contrast in preclinical models than [99mTc]Tc-(HE)3-E01. In conclusion, DARPin (HE)3-E01 labeled using a non-residualizing [123I]I-para-iodobenzoate (PIB) label is the preferred radiotracer for in vivo imaging of EGFR expression in cancer.
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
Relation: International Journal of Molecular Sciences, 1661-6596, 2025, 26:21; PMID 41226646; ISI:001615224900001
DOI: 10.3390/ijms262110609
Availability: http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-573428; https://doi.org/10.3390/ijms262110609
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.8B42CBA2
Database: BASE